Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,128 public trials 2,031 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT03942224

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

View Trial Details

Active, not recruiting

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800

Conditions: Acquired Immunodeficiency Syndrome, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), +74 more
Locations: Columbia University Irving Medical Center New York, United States

View Trial Details

Active, not recruiting

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

NCT05879744

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

City of Hope Duarte, California, United States

Winship Cancer Institute at Emory University Atlanta, Georgia, United States

Massachusetts General Hospital Boston, Massachusetts, United States

View Trial Details

Active, not recruiting

Tissue Microarray of Hematological Malignancies

NCT04142372

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +17 more
Locations: Tampere Univerisity Hospital Tampere, Finland

View Trial Details

Active, not recruiting

Cohort Construction and Prognostic Model Construction for Multiple Myeloma

NCT06366802

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China

View Trial Details

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

NCT03620578

Conditions: BCL-2 Translocation, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations: BE-Antwerpen-ZNASTUIVENBERG Antwerp, Belgium

BE-Leuven-UZLEUVEN Leuven, Belgium

NL-Den Bosch-JBZ 's-Hertogenbosch, Netherlands

NL-Almere-FLEVOZIEKENHUIS Almere Stad, Netherlands

View all 24 locations

View Trial Details

Active, not recruiting

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

NCT05214183

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Department of Hematology X, Odense University Hospital Odense, Denmark

Department of Hematology, Zeeland University Hospital Roskilde Roskilde, Denmark

Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center Helsinki, Finland

Oulu University Hospital Oulu, Finland

View all 20 locations

View Trial Details

Active, not recruiting

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

NCT04105530

Conditions: Acute Lymphoblastic Leukemia, Executive Dysfunction, Hematologic Diseases, +11 more
Locations: St. Jude Children's Research Hospital Memphis, Tennessee, United States

View Trial Details

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

NCT03915184

Conditions: Blood Protein Disorders, Carcinoma, Cardiovascular Diseases, +14 more
Locations: Mayo Clinic Hospital Phoenix, Arizona, United States

UCSF San Francisco, California, United States

Colorado Blood Cancer Institute Denver, Colorado, United States

Moffitt Cancer Center Tampa, Florida, United States

View all 13 locations

View Trial Details

Active, not recruiting

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

NCT06154902

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: DESCAR-T Registry Paris, France

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions